• / Free eNewsletters & Magazine
  • / My Account
Home>Implanet Strengthens JAZZ Intellectual Property Portfolio

Implanet Strengthens JAZZ Intellectual Property Portfolio

Implanet Strengthens JAZZ Intellectual Property Portfolio


Implanet Strengthens JAZZ Intellectual Property Portfolio

  • 2 new patents granted in the United States
  • Portfolio of 24 patents granted

Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that the US Patent and Trademark Office (USPTO) has granted two new patents for the JAZZ™ platform.

These two new patents further strengthen the portfolio of 22 patents covering all the aspects of the JAZZ™ platform. It is the result of an extremely proactive and rigorous policy that is one of the strategic keys to commercial development and value creation.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “These two new U.S. patents expand our protection on this highly competitive market. Intellectual Property is essential to Implanet’s formula, we meticulously manage our portfolio. Clinical results support the fact that we possess the band market’s most advanced implants and instrumentation. We will continue to expand the scope of protection covering our JAZZ™ platform and future innovations.

Ludovic Lastennet, CEO of Implanet, adds: “Obtaining these patents is an integral part of our value-creation strategy, we aim to put solid barriers in place in an addressable spine market estimated at $2.1 billion. The systematic growth of our IP protection enables us to reinforce our current commercial partnerships and look towards future strategic alliances.

Next financial press release: revenue for the 3rd quarter of 2017, on October 10, 2017, before market opens.


©2017 Morningstar Advisor. All right reserved.